3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
9
Carcinoma, Renal Cell
8
Colorectal Neoplasms
7
Urinary Bladder Neoplasms
6
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
3
Glioblastoma
3
Carcinoma, Neuroendocrine
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Neuroendocrine Tumors
2
Kidney Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Testicular Neoplasms
1
Testicular Diseases
1
Interventions
Fluorouracil
128
Leucovorin
120
Oxaliplatin
101
Irinotecan
89
Bevacizumab
55
Cetuximab
44
Capecitabine
40
Folfox protocol
29
Panitumumab
22
Colonoscopy
17
Chemotherapy, Adjuvant
16
Floxuridine
15
Early Intervention, Educational
15
Erlotinib Hydrochloride
13
Surveys and Questionnaires
11
IFL protocol
11
Counseling
11
Celecoxib
11
Immunohistochemistry
10
Gemcitabine
10
Psychiatric Rehabilitation
9
Methods
8
Magnetic Resonance Spectroscopy
8
Gene Expression Profiling
8
Exercise
8
Dexamethasone
8
sargramostim
7
Sorafenib
7
Radiotherapy
7
Nivolumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colonic Neoplasms
×
avelumab
×
Clear all
NCT03854799
2023-10-19
AVANA
Gruppo Oncologico del Nord-Ovest
Phase 2
Completed
101 enrolled